Drugs / Protandim
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06429059 | Jun 2024 → May 2025 | amyotrophic lateral sclerosis | Duke University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Protandim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06429059 ↗ |
| Route | Oral | “Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa...” NCT06429059 ↗ |